Log In
News

Virtual Roadshow with Cocrystal Pharma (COCP) Interim Co-CEOs Sam Lee, President & James Martin, CFO

12/14/2021
Health
0 min read

Cocrystal Pharma Interim Co-CEOs Sam Lee, President and James Martin, CFO make a formal corporate presentation. Afterwards they are joined by Noble Capital Markets Senior Research Analyst Robert LeBoyer for a Q & A session.

Research, News, and Advanced Market Data on COCP


Information on upcoming live virtual roadshows


Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Share
Related News
‌
Small Biotech Cullinan Goes All-In on Autoimmune CAR-T in $280M Pivot
4/17/2024
Health

Small Biotech Cullinan Goes All-In on Autoimmune CAR-T in $280M Pivot

In a bold strategic move, small-cap biotech Cullinan Oncology is transforming into an autoimmune disease company and rebranding as Cullinan Therapeutics. The Massachusetts company announced the major pivot alongside a...
3 min read
‌
Bitcoin’s Next Major Milestone Is A Few Days Away: The 2024 Halving
4/17/2024
Blockchain

Bitcoin’s Next Major Milestone Is A Few Days Away: The 2024 Halving

A once-every-four-years event in the Bitcoin world is rapidly approaching – the highly anticipated “halving.” Scheduled to occur around April 19th, 2024, this mechanism hard-coded into Bitcoin’s DNA is set...
3 min read
‌
Xcel Brands (XELB) – Sets Its Course Toward Profitability
4/17/2024
Consumer

Xcel Brands (XELB) – Sets Its Course Toward Profitability

A noisy quarter. The company reported Q4 revenue of $2.3 million down year over year, but reflected strong 48% licensing revenue growth. Adj. EBITDA loss of $1.2 million was modestly lower...
2 min read
‌
Haynes International (HAYN) – Shareholders Vote to Approve Haynes’ Pending Acquisition by North American Stainless
4/17/2024
Industrials

Haynes International (HAYN) – Shareholders Vote to Approve Haynes’ Pending Acquisition by North American Stainless

Transaction approved by Haynes stockholders. At a special meeting on April 16, Haynes shareholders voted to approve the company’s pending acquisition by North American Stainless, Inc., a wholly owned subsidiary of...
2 min read

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
Log In
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.
Log In